Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Geron (GERN) Share Price

News articles about Geron (NASDAQ:GERN) have been trending somewhat positive recently, according to Accern. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Geron earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.6490728919598 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

These are some of the news stories that may have effected Accern Sentiment Analysis’s scoring:

GERN has been the topic of a number of analyst reports. Zacks Investment Research lowered shares of Geron from a “buy” rating to a “hold” rating in a report on Tuesday, October 10th. Stifel Nicolaus restated a “hold” rating and issued a $2.50 price objective on shares of Geron in a report on Friday, November 3rd. Needham & Company LLC restated a “hold” rating on shares of Geron in a report on Friday, November 3rd. Finally, BidaskClub lowered shares of Geron from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $3.75.

Shares of Geron (NASDAQ GERN) opened at $1.87 on Wednesday. Geron has a fifty-two week low of $1.74 and a fifty-two week high of $3.15.

Geron (NASDAQ:GERN) last announced its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.05) by $0.01. Geron had a negative net margin of 2,992.67% and a negative return on equity of 25.14%. The business had revenue of $0.16 million for the quarter, compared to analyst estimates of $0.40 million. During the same period last year, the business earned ($0.02) EPS. The company’s revenue was down 96.8% on a year-over-year basis. research analysts forecast that Geron will post -0.17 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Geron (GERN) Share Price” was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at

About Geron

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity.

Insider Buying and Selling by Quarter for Geron (NASDAQ:GERN)

What are top analysts saying about Geron Co.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Geron Co. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit